- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02824159
Association Between Side Effects Occurrence and Concentrations of Ibrutinib and Idelalisib (PK-E3I)
Real Life Assessment of the Association and Its Determinants Between Side Effects and Plasmatic Concentrations of Two Protein Kinase Inhibitors: Ibrutinib (IMBRUVICA®) and Idelalisib (ZYDELIG®) in Hematological Malignancies Treatment.
Recently, European Medicines Agency approved ibrutinib and idelalisib to treat Chronic Lymphocytic Leukemia (CLL) and two lymphomas: Follicular Lymphoma (FL) for ibrutinib and Mantle cell lymphoma (MCL) for idelalisib.
Clinical trials for ibrutinib and idelalisib were performed with a small number of patients (300-350) and showed several side effects profiles. Since, pharmacokinetic properties of these 2 drugs highlight a interindividual variability of pharmacokinetic. The aim of this study is to determine the association between clinically significant side effects occurrence during the first year of treatment and plasma mean concentration of the steady state of ibrutinib or idelalisib at 1 month.
Study Overview
Status
Conditions
Detailed Description
Recently, European medicines agency approved ibrutinib and idelalisib in the treatment of Chronic Lymphocytic Leukemia (CLL) and two lymphomas: Follicular Lymphoma (FL) for ibrutinib and Mantle cell lymphoma (MCL) for idelalisib. Nevertheless, clinical trials for these two drugs were performed for only 300-350 patients and showed several side effects profiles, the most frequent were diarrhea, infection, cutaneous rash… For some patients, treatment had to be reduced or stopped temporary or definitely.
Pharmacokinetic properties of these two drugs highlight an interindividual pharmacokinetic considerable variability. The aim of this clinical research study is to determine the association between clinically significant side effects occurrence during the first year of treatment (serious adverse reaction and/or grade CTCAE ≥ 3 and/or leading a dosage concession) and plasma mean concentration of the steady state of ibrutinib or idelalisib performed at 1 month.
To determine plasma mean concentration of the steady state of ibrutinib or idelalisib, blood tests will be performed every scheduled monitoring at visit 1 month during a pharmacokinetic exploration and during scheduled medical consultation (2, 3, 6 and 12 months) and every unscheduled visit in case of side effect occurrence.
Every scheduled monitoring visit, blood tests will be performed to determine plasma concentration in drug. Complementary blood or salivary samples will be collected before the treatment, 24 months later and in case of relapse to determine genetic characteristics. In parallel, a logbook will be completed by the patient to collect side effects. Finally, an oncology certified nurse call patients every 2 weeks. In case of side effect occurrence a visit will be organized in the next 3 days and a blood test will be performed.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Toulouse, France, 31059
- Cancer University Institute of Toulouse Oncopole
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Evidence of Chronic Lymphocytic Leukaemia (CLL), or Follicular Lymphoma (FL) or Mantle cell lymphoma (MCL) and a first prescription of idelalisib or ibrutinib
- Patients must give written informed consent
- Patients with Health Insurance System
Exclusion Criteria:
- Patient who several blood tests can't be performed (poor venous access)
- Patients under legal guardian
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patient with haematologic malignancies
Interventions to be administrated are :
|
6 blood sample at regular intervals
Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
Quality of life will be evaluated with questionaries 5 times during the study
The detection will be assessed using the AMA (assistance des malades ambulatoires) system
Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
The following parameters will be assessed :
The clinical examination are composed by :
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of clinically significant side effect occurence with plasma balance mean concentration in ibrutinib
Time Frame: 1 months after treatment initiation
|
Plasma balance mean will be calculated with 6 blood samples collected at regular intervals during the visit
|
1 months after treatment initiation
|
Evaluation of clinically significant side effect occurence with plasma balance mean concentration in idelalisib
Time Frame: 1 months after treatment initiation
|
Plasma balance mean will be calculated with 6 blood samples collected at regular intervals during the visit
|
1 months after treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinically significant side effect occurrence (Serious adverse reaction and/or grade CTCAE ≥ 3 and/or leading a dosage concession) as assessed by AMA (Assistance des Malades Ambulatoires) system
Time Frame: through the end of study (24 months)
|
through the end of study (24 months)
|
|
Plasma balance mean concentration in ibrutinib with collection of blood samples
Time Frame: 1 month after inclusion
|
Plasma balance mean will be calculated with 6 blood samples collected at regular intervals during the visit
|
1 month after inclusion
|
Plasma balance mean concentration in idelalisib with collection of blood samples
Time Frame: 1 month after inclusion
|
Plasma balance mean will be calculated with 6 blood samples collected at regular intervals during the visit
|
1 month after inclusion
|
The health-related quality (HRQoL) by the self-reported French version of the Short Form (36) Health Survey
Time Frame: Day 1
|
Day 1
|
|
The health-related quality (HRQoL) by the self-reported French version of the Short Form (36) Health Survey
Time Frame: 3 months after inclusion
|
3 months after inclusion
|
|
The health-related quality (HRQoL) by the self-reported French version of the Short Form (36) Health Survey
Time Frame: 6 months after inclusion
|
6 months after inclusion
|
|
The health-related quality (HRQoL) by the self-reported French version of the Short Form (36) Health Survey
Time Frame: 12 months after inclusion
|
12 months after inclusion
|
|
The health-related quality (HRQoL) by the self-reported French version of the Short Form (36) Health Survey
Time Frame: 18 months after inclusion
|
18 months after inclusion
|
|
The health-related quality (HRQoL) by the self-reported French version of the Short Form (36) Health Survey
Time Frame: 24 months after inclusion
|
24 months after inclusion
|
|
Response to treatment assessed by positron emission tomography-Scan
Time Frame: Day 0
|
complete response, partial, stable disease, disease progression
|
Day 0
|
Response to treatment assessed by positron emission tomography-Scan
Time Frame: 6 months after inclusion
|
complete response, partial, stable disease, disease progression
|
6 months after inclusion
|
Response to treatment assessed by positron emission tomography-Scan
Time Frame: 12 months after inclusion
|
complete response, partial, stable disease, disease progression
|
12 months after inclusion
|
Response to treatment assessed by positron emission tomography-Scan
Time Frame: 24 months after inclusion
|
complete response, partial, stable disease, disease progression
|
24 months after inclusion
|
Forgetting to take medication reported by the patient as recorded in a logbook given to the patient
Time Frame: 3 months after inclusion
|
3 months after inclusion
|
|
Forgetting to take medication reported by the patient as recorded in a logbook given to the patient
Time Frame: 6 months after inclusion
|
6 months after inclusion
|
|
Perception of side effect reported by patient as noted in a logbook by the patient
Time Frame: 3 months after inclusion
|
3 months after inclusion
|
|
Perception of side effect reported by patient as noted in a logbook by the patient
Time Frame: 6 months after inclusion
|
6 months after inclusion
|
|
Effect of patients characteristics on plasma balance mean concentration in ibrutinib
Time Frame: 1 months after inclusion
|
1 months after inclusion
|
|
Effect of patients characteristics on plasma balance mean concentration in idelalisib
Time Frame: 1 months after inclusion
|
1 months after inclusion
|
|
Effect of patients genetic polymorphism on plasma balance mean concentration in idelalisib
Time Frame: 1 months after inclusion
|
1 months after inclusion
|
|
Effect of patients therapeutic target DNA polymorphism on treatment response to ibrutinib
Time Frame: Through the completion of study (24 months)
|
Through the completion of study (24 months)
|
|
Effect of patients therapeutic target DNA polymorphism on treatment response to idelalisib
Time Frame: Through the completion of study (24 months)
|
Through the completion of study (24 months)
|
|
Treatment failure rate in relation with mean concentration of ibrutinib
Time Frame: 1 month after inclusion
|
1 month after inclusion
|
|
Treatment failure rate in relation with mean concentration of idelalisib
Time Frame: 1 month after inclusion
|
1 month after inclusion
|
|
Evaluation of total exposition to ibrutinib (AUCt,ss) with residual concentration at steady state
Time Frame: Through the completion of study (24 months)
|
Through the completion of study (24 months)
|
|
Evaluation of total exposition to idelalisib (AUCt,ss) with residual concentration at steady state
Time Frame: Through the completion of study (24 months)
|
Through the completion of study (24 months)
|
|
Association of adverse event and quality of life with Short Form (36) Health Survey
Time Frame: Through the completion of study (24 months)
|
Through the completion of study (24 months)
|
|
Association of prognostic factors at inclusion and plasma balance mean concentration in ibrutinib
Time Frame: 1 month after inclusion
|
1 month after inclusion
|
|
Association of prognostic factors at inclusion and plasma balance mean concentration in idelalisib
Time Frame: 1 month after inclusion
|
1 month after inclusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Loïc Ysebaert, MD, Cancer University Institute of Toulouse Oncopole
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15 7754 07
- 2015-005572-17 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Malignancies
-
Tel-Aviv Sourasky Medical CenterMeir Medical Center; Max Planck Institute for Infection BiologyUnknownPediatric Solid Malignancies | Pediatric Hematological MalignanciesIsrael
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineCompletedMyeloid Hematological MalignanciesUnited States
-
Centre Hospitalier Universitaire de BesanconTerminatedHematological Malignancies BFrance
-
AdaptimmuneTerminatedSolid and Hematological MalignanciesUnited States, Canada
-
Senti BiosciencesNot yet recruitingAML/MDS | CD33 Expressing Hematological Malignancies | FLT3 Expressing Hematological Malignancies
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory Hematological MalignanciesChina
-
AdaptimmuneRecruitingSolid and Hematological MalignanciesUnited States, Spain, Canada, United Kingdom
-
Kite, A Gilead CompanyEnrolling by invitationSolid and Hematological MalignanciesUnited States, Netherlands, Japan, Australia, France, Israel, Germany, Canada, United Kingdom
-
AstraZenecaParexelCompletedSolid and Hematological MalignanciesGermany
-
CASI Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hematological MalignanciesCanada
Clinical Trials on Blood samples for pharmacokinetics exploration
-
Ryazan State Medical UniversityRecruitingResistant Arterial HypertensionRussian Federation
-
Clinique Romande de ReadaptationRecruitingComplex Regional Pain Syndrome Type ISwitzerland
-
Huazhong University of Science and TechnologyHubei Cancer Hospital, Tongji Medical College, Huazhong University of Science... and other collaboratorsRecruitingRadiation PneumonitisChina
-
Akcea TherapeuticsRecruitingHereditary Transthyretin Amyloidosis With PolyneuropthyUnited States, Canada
-
Rigshospitalet, DenmarkCompleted
-
Ela ShaiCompletedInherited Platelet DisordersIsrael
-
First Affiliated Hospital of Harbin Medical UniversityUnknown
-
Washington University School of MedicineRecruiting
-
Centre Hospitalier Universitaire de BesanconCompletedAvian Hypersensitivity PneumonitisFrance